Abstract
Numerous reports, ranging from molecular investigations to clinical studies, demonstrate the potency of estrogens to modulate brain function and their implications in schizophrenia and depression. Alterations of dopaminergic, cholinergic, GABAergic, glutamatergic and serotonergic neurotransmission through estrogen-mediated mechanisms have been consistently established. Moreover, studies using in vivo and in vitro models as well as epidemiological data suggest that estrogens provide neuroprotection of central nervous system (CNS) cells implicated in the etiology of neurodegenerative disorders such as Alzheimers (AD) and Parkinsons (PD) diseases. Numerous genomic or non-genomic mechanisms of actions of estrogens in the brain have been documented implicating classical nuclear estrogen receptors as well as possible estrogen membrane receptors, antioxidant activity of steroids, their effect on fluidity as well as on antiapoptotic proteins and growth factors. Selective estrogen receptor modulators (SERMs) have estrogenic and/or antiestrogenic activity depending on the target tissue. Hence, SERMs have the same beneficial effect as estrogen in skeleton and cardiovascular systems but act as antagonists in breast and uterus. The finding of beneficial side effects of SERMs in the CNS might improve their risk-benefit ratio in traditional indications. In this review, we will survey schizophrenia and depression as examples of mental diseases and AD and PD as neurodegenerative diseases. We will review brain effects of estrogens, steroids possibly acting as pro-drugs of estrogens such as testosterone and dehydroepiandrosterone (DHEA) and present novel findings with SERMs. Drugs with estrogen activity in the brain may have therapeutic potential either by modulating brain neurotransmitter transmission or through neuroprotective activity.
Keywords: Estrogen, Brain activity, CNS, Schizophrenia, Depression, Dopaminergic, Cholinergic, GABAergic, Glutamatergic, Serotonergic, Neurotransmission, Central nervous system, Alzheimers AD, Selective estrogen receptor modulators, Peripheral activities, Steroidal estrogens, 17beta estradiol, Dehydroepiandrosterone, Tamoxifen, Taloxifene, Triphenylethylenes, Benzothiphenes, Nerve growth factors NGF, Monomine oxidase
Current Pharmaceutical Design
Title: Drugs with Estrogen-like Potency and Brain Activity Potential Therapeutic Application for the CNS
Volume: 6 Issue: 12
Author(s): M. Cyr, F. Calon, M. Morissette, M. Grandbois, S. Callier and T. Di Paolo
Affiliation:
Keywords: Estrogen, Brain activity, CNS, Schizophrenia, Depression, Dopaminergic, Cholinergic, GABAergic, Glutamatergic, Serotonergic, Neurotransmission, Central nervous system, Alzheimers AD, Selective estrogen receptor modulators, Peripheral activities, Steroidal estrogens, 17beta estradiol, Dehydroepiandrosterone, Tamoxifen, Taloxifene, Triphenylethylenes, Benzothiphenes, Nerve growth factors NGF, Monomine oxidase
Abstract: Numerous reports, ranging from molecular investigations to clinical studies, demonstrate the potency of estrogens to modulate brain function and their implications in schizophrenia and depression. Alterations of dopaminergic, cholinergic, GABAergic, glutamatergic and serotonergic neurotransmission through estrogen-mediated mechanisms have been consistently established. Moreover, studies using in vivo and in vitro models as well as epidemiological data suggest that estrogens provide neuroprotection of central nervous system (CNS) cells implicated in the etiology of neurodegenerative disorders such as Alzheimers (AD) and Parkinsons (PD) diseases. Numerous genomic or non-genomic mechanisms of actions of estrogens in the brain have been documented implicating classical nuclear estrogen receptors as well as possible estrogen membrane receptors, antioxidant activity of steroids, their effect on fluidity as well as on antiapoptotic proteins and growth factors. Selective estrogen receptor modulators (SERMs) have estrogenic and/or antiestrogenic activity depending on the target tissue. Hence, SERMs have the same beneficial effect as estrogen in skeleton and cardiovascular systems but act as antagonists in breast and uterus. The finding of beneficial side effects of SERMs in the CNS might improve their risk-benefit ratio in traditional indications. In this review, we will survey schizophrenia and depression as examples of mental diseases and AD and PD as neurodegenerative diseases. We will review brain effects of estrogens, steroids possibly acting as pro-drugs of estrogens such as testosterone and dehydroepiandrosterone (DHEA) and present novel findings with SERMs. Drugs with estrogen activity in the brain may have therapeutic potential either by modulating brain neurotransmitter transmission or through neuroprotective activity.
Export Options
About this article
Cite this article as:
Cyr M., Calon F., Morissette M., Grandbois M., Callier S. and Paolo Di T., Drugs with Estrogen-like Potency and Brain Activity Potential Therapeutic Application for the CNS, Current Pharmaceutical Design 2000; 6 (12) . https://dx.doi.org/10.2174/1381612003399725
DOI https://dx.doi.org/10.2174/1381612003399725 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders
Current Pharmaceutical Design Marginal Vitamin A Deficiency Exacerbates Memory Deficits Following Aβ1-42 Injection in Rats
Current Alzheimer Research The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview
Current Drug Targets Protein Cysteine Modifications: (1) Medicinal Chemistry for Proteomics
Current Medicinal Chemistry Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Commentary (Research Highlights: Wnt-Signalling: A New Direction for Alzheimer Disease?)
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Complexity against Complexity: Multitarget Drugs)
Current Medicinal Chemistry Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Yeast as a Model System to Study Trafficking of Small Vesicles Carrying Signal-less Proteins In and Out of the Cell
Current Protein & Peptide Science Extracellular Vesicles as Therapeutics for Brain Injury and Disease
Current Pharmaceutical Design p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Bioinformatics Paradigms in Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Contemporary siRNA Therapeutics and the Current State-of-Art)
Current Pharmaceutical Design Effect of Apigenin on Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Determination of Lipoic Acid in the form of 2-S-pyridinium Derivative by High-performance Liquid Chromatography with Ultraviolet Detection
Current Analytical Chemistry Tea and Health: Studies in Humans
Current Pharmaceutical Design